Current State of Therapeutics for HTLV-1.

Humans Human T-lymphotropic virus 1 / genetics HTLV-I Infections / therapy Animals Leukemia-Lymphoma, Adult T-Cell / therapy Antiviral Agents / therapeutic use Viral Vaccines / immunology
ATL HAM HTLV-1 antiviral therapeutics retrovirus

Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
15 Oct 2024
Historique:
received: 02 09 2024
revised: 07 10 2024
accepted: 11 10 2024
medline: 26 10 2024
pubmed: 26 10 2024
entrez: 26 10 2024
Statut: epublish

Résumé

Human T cell leukaemia virus type-1 (HTLV-1) is an oncogenic retrovirus that causes lifelong infection in ~5-10 million individuals globally. It is endemic to certain First Nations populations of Northern and Central Australia, Japan, South and Central America, Africa, and the Caribbean region. HTLV-1 preferentially infects CD4

Identifiants

DOI: 10.3390/v16101616 PMID: 39459949
pubmed: 39459949
pii: v16101616
doi: 10.3390/v16101616
pii:
doi:

Substances chimiques

Antiviral Agents 0
Viral Vaccines 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIH HHS
ID : R01 1R01MH134389-01 NIMH.
Pays : United States
Organisme : NHMRC program grant
ID : APP1149990
Organisme : Australian Centre for HIV and Hepatitis Virology Research (ACH4) Project Grants
Organisme : Australian NHMRC Ideas grant
ID : GNT2004670

Déclaration de conflit d'intérêts

The authors declare no conflicts of interest.

Auteurs

Tiana T Wang (TT)

Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia.
ORCID: 0000-0002-4292-272X

Ashley Hirons (A)

The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3052, Australia.

Marcel Doerflinger (M)

Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
Department of Medical Biology, University of Melbourne, Melbourne, VIC 3050, Australia.

Kevin V Morris (KV)

Centre for Genomics and Personalised Health, School of Biomedical Sciences, Queensland University of Technology, Kelvin Grove, QLD 4059, Australia.
ORCID: 0000-0002-0157-0553

Scott Ledger (S)

Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia.

Damian F J Purcell (DFJ)

The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3052, Australia.
ORCID: 0000-0002-4485-1726

Anthony D Kelleher (AD)

Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia.
UNSW RNA Institute, University of New South Wales, Sydney, NSW 2052, Australia.

Chantelle L Ahlenstiel (CL)

Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia.
UNSW RNA Institute, University of New South Wales, Sydney, NSW 2052, Australia.
ORCID: 0000-0002-4238-7237

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Current State of Therapeutics for HTLV-1.
questionsmedicales.fr › Virus › Virus à ARN › Retroviridae › Deltaretrovirus › Virus T-lymphotrope de type 1 des primates › Virus T-lymphotrope humain de type 1 › Current State of Therapeutics for HTLV-1.
questionsmedicales.fr › Maladies du système immunitaire › Déficits immunitaires › Infections à deltarétrovirus › Infections à HTLV-I › Current State of Therapeutics for HTLV-1.
questionsmedicales.fr › Eucaryotes › Animaux › Current State of Therapeutics for HTLV-1.
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Syndromes lymphoprolifératifs › Leucémie lymphoïde › Leucémie à cellules T › Leucémie-lymphome à cellules T de l'adulte › Current State of Therapeutics for HTLV-1.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antiviraux › Current State of Therapeutics for HTLV-1.
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Vaccins › Vaccins antiviraux › Current State of Therapeutics for HTLV-1.